Apelin-13, an endogenous peptide, improved neurological function after a stroke, reduced infarct volume, decreased cerebral edema, maintained the integrity of the BBB, inhibited neuronal apoptosis, and diminished neuroinflammation by lowering microglial activation in the MCAO model [133]. This evidence concerns the gene APLN and Stroke.